About Contact Us Careers

Phenylketonuria Treatment Market Size & Share, by Drug Type (Palynziq, Kuvan, SYNB1618); Route of Administration (Intravenous, Oral, Subcutaneous); End Users (Online Pharmacies, Hospital Pharmacies, Speciality Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3031
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Phenylketonuria Treatment Market size was valued at USD 794.16 million in 2024 and is set to exceed USD 1.98 billion by 2037, expanding at over 7.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of phenylketonuria treatment is evaluated at USD 843.44 million.

The growth of the market can be attributed to the rising prevalence of phenylketonuria globally and high incidence rate of the disorder in some emerging countries such as Turkey. Further, the increasing government initiatives in order to increase awareness & knowledge towards market, along with the surge in the mergers and acquisitions between different key players for the development of new drugs is propelling demand for phenylketonuria treatment are anticipated to drive the market growth. Moreover, rising research activities in the field of biotechnology and genomics is also anticipated to contribute to the growth of the market in the coming years.

Global-Phenylketonuria-Drugs-Market-Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Rising Demand for Phenylketonuria Treatment Drugs
  • Growing Advancements in Healthcare

Challenges

  • High Cost of phenylketonuria treatment

Phenylketonuria Treatment Market: Key Insights

Report Attribute Details

Base Year

2024

Forecast Year

2025-2037

CAGR

7.3%

Base Year Market Size (2024)

USD 794.16 million

Forecast Year Market Size (2037)

USD 1.98 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Phenylketonuria Treatment Segmentation

The market is segmented on the basis of drug type into Palynziq, Kuvan, SYNB1618 and others. Among these segments, the Kuvan drug segment is estimated to capture the largest market share in the year 2021. Kuvan drug contains the oral pharmaceutical formulation BH4, which is known to stimulate the activity of phenylalanine hydroxylase enzyme to metabolize phenylalanine into tyrosine.

Our in-depth analysis of the global market includes the following segments:

           By Drug Type
  • Palynziq
  • Kuvan
  • SYNB1618
  • Others

             By Route of Administration
  • Intravenous
  • Oral
  • Subcutaneous

           By End Users
  • Online Pharmacies
  • Hospital Pharmacies
  • Speciality Clinics
  • Others
 

 

 

Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Phenylketonuria Treatment Industry - Regional Synopsis

Geographically, the phenylketonuria treatment market is segmented into five major region including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Among the market in these regions, North America industry is likely to hold largest revenue share by 2037, attributed to rising research and development activities for novel drugs, coupled with favourable government regulations for the treatment of phenylketonuria. In addition, improvements in healthcare infrastructure in the region along with growing cases of new-born suffering from the disorder is also projected to foster the market growth. 

On the other hand, the market in the Asia Pacific is anticipated to foresee significant growth on account of the rising population in emerging nations and growing awareness for the treatment of phenylketonuria. Moreover, progress in the economies along with several screening programs in the region is also estimated to accelerate the market growth over the forecast period.

Phenylketonuria-Drugs-Market-Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Phenylketonuria Treatment Landscape

     

    • Ultragenyx Pharmaceutical
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PTC Therapeutics
    • BioMarin
    • Homology Medicines, Inc.
    • SOM BIOTECH
    • Nestle Health Science
    • American Gene Technologies Inc.
    • Rubius Therapeutics, Inc.
    • Synlogic

     

  • Report ID: 3031
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of phenylketonuria treatment is evaluated at USD 843.44 million.

Phenylketonuria Treatment Market size was valued at USD 794.16 million in 2024 and is set to exceed USD 1.98 billion by 2037, expanding at over 7.3% CAGR during the forecast period i.e., between 2025-2037.

North America industry is likely to hold largest revenue share by 2037, attributed to rising research and development activities for novel drugs, coupled with favourable government regulations for the treatment of phenylketonuria.

The major players in the market are Ultragenyx Pharmaceutical, PTC Therapeutics, BioMarin, Homology Medicines, Inc., SOM BIOTECH, Nestle Health Science, American Gene Technologies Inc., Rubius Therapeutics, Inc., Synlogic, and others.

Phenylketonuria Drugs Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos